Consensus molecular subtype of colorectal cancer and its clinical application prospects
- VernacularTitle:结直肠癌的共识分子分型及其临床应用展望
- Author:
Tianle JIN
1
,
2
;
Yuquan LIU
3
,
4
;
Runshi WANG
3
;
Ni HOU
5
;
Jie LI
1
Author Information
- Publication Type:Journal Article
- Keywords: colorectal cancer (CRC); heterogeneity; consensus molecular subtype (CMS); clinical application
- From: Journal of Xi'an Jiaotong University(Medical Sciences) 2024;45(4):525-534
- CountryChina
- Language:Chinese
- Abstract: Colorectal cancer (CRC) is highly heterogeneous, but traditional TNM staging cannot distinguish the heterogeneity of CRC well, which can no longer meet the treatment needs. Integrating the clinical features, molecular genetic changes in cancer tissue, transcriptome and proteome changes, as well as immune matrix characteristics, the consensus molecular subtype (CMS) of CRC is by far the best description of its heterogeneity. This paper first discusses the molecular genetic changes of three types of CRC cancer tissues (chromosomal instability, microsatellite instability, and CpG island methylation phenotype). Then it systematically elaborates on the clinical characteristics, treatment directions, and prognosis evaluation of CRC patients with different CMS subtypes, as well as their relationship with immunotherapy and changes in gut microbiota. With the continuous improvement of sequencing technology and the prospective precision medicine clinical trial exploration, the "multi-molecule — multi-drug" treatment model based on CMS typing will become the core of future precision medicine and personalized medicine.
